| Literature DB >> 29736359 |
Jagannath Pramod1, Chellappa Vijayakumar1, Krishnamachari Srinivasan1, Nanda Kishore Maroju1, Nagarajan Raj Kumar1, Gopal Balasubramaniyan1.
Abstract
Introduction Fungal infection of the peritoneum has become more common in recent years, the most common cause of which is Candida. Candida peritonitis is considered as a severe disease and is regarded as an independent risk factor for mortality in postoperative peritonitis. This study was planned to find out the clinical significance of Candida isolation on the outcome of the patients with peritonitis in terms of morbidity and mortality. Methods This prospective study included consecutive patients admitted and operated for secondary peritonitis over a two-year period in a tertiary care hospital in South India. The time delay was assessed from the onset of symptoms to surgery. The intraoperative peritoneal fluid aspirate was analyzed for culture sensitivity (fungal and bacterial). Patients were followed until their discharge from the hospital or death. This study analyzed the clinico-microbiological profile in patients with perforation peritonitis with special reference to Candida isolation. The analysis also looked the results of antifungal therapy (fluconazole) in patients positive for Candida isolation. Results The study included 407 consecutive patients with hollow viscus perforation diagnosed intraoperatively. Fungal organisms were identified in 153 patients (37.6%). Old age (> 50 years), high lag period (≥ 48 hours), peritoneal contamination, length of hospital stay, the presence of co-morbidities, shock at presentation, and postoperative complications were found to be significantly associated with fungal infection (p < 0.05). The study noted a significant decrease in the perioperative complications in patients who were started on antifungal treatment early (within 72 hours after surgery). There were significant reductions in the length of hospital stay, intensive care unit (ICU) stay, ventilator support, and inotropic support in the postoperative period. However, we did not find any difference in mortality due to early treatment with fluconazole. Conclusion Candida peritonitis was associated with an increase in the mortality and morbidity, especially when associated with diabetes mellitus and fungemia. Early antifungal therapy (within 72 hours after surgery) reduced the morbidity due to Candida peritonitis but did not affect the mortality.Entities:
Keywords: anti-fungal property; candida colonization; fungal infection; morbidity; mortality; peritoneal lavage; peritonitis; prognosis; quality of life; surgical site infections
Year: 2018 PMID: 29736359 PMCID: PMC5935435 DOI: 10.7759/cureus.2275
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Study Flowchart
Comparison of Perioperative Parameters Between Candida-positive/negative Groups
N: number; SSI: surgical site Iinfection; DM: diabetes mellitus; ECF: enterocutaneous fistula; RS: respiratory system
| Perioperative parameters | Candida negative (n = 254) | Candida positive (n = 153) | p - value |
| Preoperative | |||
| Mean age (years) | 42.8 | 46.5 | 0.01 |
| Mean delay (hrs) | 45.3 | 53.1 | 0.0002 |
| Comorbidity (N (%)) | 46 (18.1%) | 65 (42.5%) | 0.0001 |
| DM (N (%)) | 18 (7.1%) | 40 (26.1%) | 0.003 |
| Shock (N (%)) | 39 (15.4%) | 53 (34.6%) | 0.00 |
| Intraoperative | |||
| Mean perforation (mm) | 5.08 | 5.83 | 0.03 |
| Mean contamination (ml) | 1,609 | 1,865 | 0.0001 |
| Postoperative | |||
| Mean hospital stay (days) | 13.2 | 18.1 | 0.001 |
| SSI (N (%)) | 102 (66.7%) | 126 (49.6%) | 0.001 |
| Dehiscence (N (%)) | 44 (28.8%) | 32 (12.6%) | 0.001 |
| Abscess (N (%)) | 36 (23.5%) | 37 (14.6%) | 0.022 |
| ECF (N (%)) | 28 (18.3%) | 14 (5.5%) | 0.001 |
| RS complications (N (%)) | 56 (36.6%) | 50 (19.7%) | 0.001 |
Basis of Starting Antifungal Treatment in Candida-positive Patients
N: number; KOH: potassium hydroxide
| Basis for starting fluconazole (n = 153) | N (%) |
| Gram stain of peritoneal fluid | 3 (2%) |
| KOH mount of peritoneal fluid | 32 (20.9%) |
| Aerobic culture of peritoneal fluid | 17 (11.1%) |
| Fungal culture of peritoneal fluid | 90 (58.8%) |
| Fungal culture of blood | 7 (4.6%) |
| Fungal culture of urine | 4 (2.6%) |
Treatment-based Categorization of Candida-positive Patients
N: number; KOH: potassium hydroxide; Tx: treatment
| Category | Basis (n = 153) | N (%) |
| No Tx group | Patient’s expiry or discharge before reporting | 56 (36.6%) |
| Tx group | Early + late Tx | 97 (63.4%) |
| Early Tx group (< 72 hrs. after surgery) | Gram stain/KOH mount/aerobic culture report | 52 (34%) |
| Late Tx group (> 72 hrs. after surgery) | Fungal culture of peritoneal fluid/blood/urine report | 45 (29.4%) |
Mannheim’s Peritonitis Index (MPI) Score and Its Association with Mortality in Candida-positive/negative Groups
N: number
| Candida-negative | Candida-positive | Total | |||
| MPI score | N | Mortality (N (%)) | N | Mortality (N (%)) | (N (%)) |
| < 21 (n = 193) | 140 | 5 (21.7%) | 53 | 2 (6.7%) | 7 (13.2%) |
| 22 – 29 (n = 125) | 64 | 4 (17.4%) | 61 | 13 (43.3%) | 17 (32.1%) |
| > 29 (n = 89) | 50 | 14 (60.9%) | 39 | 15 (50%) | 29 (54.7%) |
| Total (n = 407) | 254 | 23 (9%) | 153 | 30 (19%) | 53 (13%) |
Comparison of Postoperative Complications Between the Early/Late Treatment Groups
N: number; SSI: surgical site infection; ICU: Intensive Care Unit; ECF: enterocutaneous fistula; RS: respiratory system; Tx: treatment
| Clinical Parameters | Early Tx group (n = 52) | Late Tx group (n = 45) | p - value |
| Mean ventilator support (Days) | 1.2 | 3.3 | 0.025 |
| Mean inotropic support (Days) | 0.4 | 2.2 | 0.005 |
| Mean ICU stay (Days) | 3.9 | 9.2 | 0.001 |
| Mean hospital Stay (Days) | 13.9 | 31.6 | 0.00 |
| SSI (N (%)) | 36 (69.2%) | 41 (91.1%) | 0.008 |
| Dehiscence (N (%)) | 12 (23.1%) | 25 (55.6%) | 0.001 |
| Abscess (N (%)) | 11 (21.2%) | 15 (33.3%) | 0.17 |
| ECF (N (%)) | 6 (11.5%) | 17 (37.8%) | 0.002 |
| RS complications (N (%)) | 18 (34.6%) | 29 (64.4%) | 0.003 |
| Septicemia (N (%)) | 14 (26.9%) | 22 (48.9%) | 0.026 |
| Mortality (N (%)) | 12 (23.1%) | 9 (20%) | 0.71 |
Comparison of Perioperative Parameters Between Untreated and Treated Groups
N: number; Tx: treatment; SSI: surgical site infection; DM: diabetes mellitus; ECF: enterocutaneous fistula; ICU: Intensive Care Unit; S: Sterile; -: negative; +: positive; RS: respiratory system
| Perioperative parameters | No Tx group (n = 56) | Tx group (n = 97) | p - value |
| Preoperative | |||
| Mean age (years) | 46.3 | 46.09 | 0.60 |
| Mean duration of symptoms (hours) | 40.3 | 46.6 | 0.04 |
| DM (N (%)) | 14 (25%) | 26 (26.8%) | 0.81 |
| Shock (N (%)) | 10 (17.9%) | 43 (44.3%) | 0.001 |
| Intraoperative | |||
| Mean contamination (ml) | 1,675 | 1,974 | 0.003 |
| Hemodynamic instability (N (%)) | 9 (16.1%) | 26 (26.8%) | 0.13 |
| Postoperative | |||
| Mean ICU stay (days) | 3.2 | 6.4 | 0.006 |
| Mean hospital stay (days) | 11.0 | 22.1 | 0.00 |
| Fluid cultures (N (%)) | 19 (33.9%) | 23 (23.7%) | 0.24 |
| Fluid culture- (N (%)) | 2 (3.6%) | 27 (28.9%) | 0.00 |
| Blood culture+ (N (%)) | 13 (23.25%) | 39 (40.2%) | 0.03 |
| Urine culture+ (N (%)) | 18 (32.1%) | 48 (49.5%) | 0.03 |
| SSI (N (%)) | 25 (44.6%) | 77 (79.4%) | 0.003 |
| Dehiscence (N (%)) | 7(12.5%) | 37 (38.1%) | 0.002 |
| Abscess (N (%)) | 10 (17.9%) | 26 (26.8%) | 0.209 |
| ECF (N (%)) | 5 (8.9%) | 23 (23.7%) | 0.02 |
| RS complications (N (%)) | 9 (16.1%) | 47 (48.5%) | 0.001 |
| Septicemia (N (%)) | 11 (19.6%) | 36 (37.1%) | 0.005 |
| Mortality (N (%)) | 9 (16.1%) | 21 (21.6%) | 0.40 |
Impact of Antifungal Treatment on Complications After One Month of Postoperative Period in Candida-positive/negative Groups
SSI: surgical site infection; N: number; Tx: treatment; RS: respiratory system; ECF: enterocutaneous fistula
| Complications | Candida negative (N (%)) | Candida positive (N (%)) | |||
| No Tx | Early Tx | Late Tx | Total | ||
| SSI | 66 (36.5%) | 9 (23.1%) | 14 (43.8%) | 34 (85%) | 57 (51.4%) |
| Dehiscence | 23 (12.7%) | 2 (5.1%) | 6 (18.8%) | 23 (57.5%) | 31 (27.9%) |
| Septicemia | 4 (2.2%) | - | 1 (3.1%) | 13 (32.5%) | 14 (12.6%) |
| RS complications | 3 (1.7%) | - | - | 13 (32.5%) | 13 (11.7%) |
| ECF | 3 (1.7%) | - | 1 (3.1%) | 10 (25%) | 11 (9.9%) |
| Overall complications | 115 (63.5%) | 30 (76.9%) | 18 (56.2%) | 34 (85%) | 54 (48.7%) |